Epidemiological studies have shown that folate deficiency increases the risk of cancer by affecting DNA repair and methylation. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism. In this study, it was hypothesized that MTHFR (C677T and A1298C) polymorphisms would be associated with bladder cancer and also with hypermethylation of the promoter of the Ras association domain family 1A (RASSF1A) gene. This hospital-based, casecontrol study of 312 bladder cancer patients and 325 cancer-free controls found that individuals carrying the MTHFR 677TT genotype had a 2.00-fold increased risk of bladder cancer compared with those carrying the 677CC genotype. None of the MTHFR A1298C polymorphisms alone were associated with bladder cancer, but the combined haplotype 677TT/1298AA was associated with a 2.27-fold increased risk compared with haplotype 677CC/1298AA. There was no association between MTHFR gene variants and methylation status of the RASSF1A gene in the 45 bladder cancer patients in whom this was studied. It is concluded that the MTHFR 677TT genotype and the TTAA haplotype may increase the risk of bladder cancer.
Introduction
Bladder cancer is the ninth most common cancer worldwide, and it is estimated that there were 357 000 newly diagnosed bladder cancer cases and 145 000 related deaths worldwide in 2002. 1 There were 68 810 newly diagnosed bladder cancer cases and 14 100 related deaths in the USA in 2008. 2 In China, bladder cancer is the tenth most common cancer, accounting for 17 365 deaths in 2005, with the mortality rate steadily increasing between 1991 and 2005. 1 It is well established that cigarette smoking and occupational or environmental exposure to chemical carcinogens are the strongest known risk factors in bladder cancer development. 3 Although many people have been exposed to these risk factors, only a DW Cai, XF Liu, RG Bu et al. MTHFR polymorphisms in Chinese bladder cancer patients fraction of exposed individuals develop bladder cancer in their lifetime, suggesting individual susceptibility to bladder carcinogenesis. 4 Epidemiological studies have shown an association between low folate intake and an increased cancer risk. Folate deficiency is thought to increase the risk of cancer through impaired DNA repair synthesis and disruption of DNA methylation. 5 -7 Methylenetetrahydrofolate reductase (MTHFR) plays an important role in the folate metabolic pathway. This enzyme catalyses the reduction of 5,10methylenetetrahydrolate to 5-methyltetrahydrofolate, the major circulatory form of folate in the body and a carbon donor for the conversion of homocysteine to methionine. 8 As a precursor of S-adenosylmethionine, methionine is the universal methyl donor for DNA methylation. MTHFR is also involved in deoxythymidine monophosphate production and plays a role in DNA synthesis. Thus, a defect in the MTHFR gene could influence both DNA methylation and DNA synthesis. Theoretically, the variable levels of activity of folate metabolic enzymes caused by MTHFR gene polymorphisms and methylation status, including global hypomethylation and hypermethylation, in specific genes would influence individual susceptibility to cancers.
Two common polymorphisms in the MTHFR gene, C677T and A1298C, affect enzyme activity. 9, 10 Associations between polymorphisms of the MTHFR gene and the risk of bladder cancer have been investigated in several studies, 4,11 -15 but the results are inconsistent. In addition, several studies have suggested that polymorphisms in genes mediating methyl group metabolism influence the epigenetic changes of DNA methylation in colorectal, breast, cervical and lung cancer. 16 -18 The available data on the role of MTHFR gene polymorphisms in relation to aberrant DNA methylation are, however, inconsistent and it is not known whether aberrant DNA methylation is influenced by the MTHFR gene polymorphisms.
The Ras association domain family 1A (RASSF1A) gene has been cloned and characterized as a tumour suppressor gene. 19 It is frequently silenced by promoter hypermethylation in bladder cancer, and promoter hypermethylation of the RASSF1A gene has been implicated in bladder cancer pathogenesis and is thought to interfere with disease outcome. 20, 21 Previously, RASSF1A gene promoter hypermethylation has been found in bladder cancer BIU87 cells. 22 To the authors' knowledge, this is the first study to investigate the association between the polymorphisms of the MTHFR gene and hypermethylation in the promoter region of the RASSF1A gene in Chinese bladder cancer patients.
Patients and methods

PATIENTS
This hospital-based, case-control study included patients with bladder cancer and cancer-free controls. All subjects were genetically unrelated ethnic Han Chinese and were from Shenyang City and surrounding regions in north-east China. The patients, who were newly diagnosed with incident bladder cancer according to histopathology, were consecutively recruited between November 2006 and January 2009 from the Shengjing Hospital of China Medical University, Shenyang City, China. There were no restrictions on enrolment with respect to age, sex or tumour stage. Those who were previous cancer patients or who had previous radiotherapy or chemotherapy were excluded. The cancer-free controls were recruited from those who were seeking MTHFR polymorphisms in Chinese bladder cancer patients healthcare for conditions other than cancer, and were frequency matched to the bladder cancer patients on the basis of age (± 5 years), sex and ethnicity.
The study protocol received ethical approval from the Institutional Review Board of the Shengjing Hospital of China Medical University. Written informed consent was obtained from all individuals included in the study.
SAMPLE COLLECTION
A 5 ml peripheral blood sample from each participant was collected into tubes containing 1.8 mg ethylenediaminetetraacetic acid (pH 8). In order to study the methylation status of the RASSF1A gene, surgically excised, frozen bladder cancer tissues were randomly selected from a number of bladder cancer cases included in the study.
GENOTYPING OF MTHFR C677T AND A1298C POLYMORPHISMS
The MTHFR C677T and A1298C polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Briefly, DNA was extracted from peripheral blood samples using a blood genome DNA extraction kit (TaKaRa Inc., Dalian, China), according to the manufacturer's instructions. The PCR analysis was performed in a total volume of 25 µl: 2.5 µl 10 × PCR buffer, 0.2 mM of each deoxynucleotide triphosphate, 2.5 mM magnesium chloride, 0.2 mM of each primer, 100 ng DNA template and 0.2 µl (5 U/µl) Taq DNA polymerase (TaKaRa, Inc.). Negative, non-template controls were included for each PCR reaction. The primers used to evaluate MTHFR gene polymorphisms were: C677T, 5′-TGAAGGAGA AGGTGTCTGCGGGA-3′ (forward), 5′-AGGA CGGTGCGGTGAGAGTG-3′ (reverse); A1298C, 5′-AAGGAGGAGCTGCTGAAGATG-3′ (forward) and 5′-CTTTGCCATGTCCACAGCATG-3′ (reverse). The thermal cycling program involved preliminary denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 61°C for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 7 min.
The amplified MTHFR gene PCR products underwent restriction enzyme digestion for 60 min at 37°C. They were separated using 3% agarose gel electrophoresis and visualized with UV light. Amplification of the C677T region produced a PCR product of 198 bp, which was then digested with the restriction enzyme Hinf I (TaKaRa, Inc.) to produce either two bands of 175 and 23 bp (677TT) or one single undigested band of 198 bp (677CC). Amplification of the A1298C region produced a PCR product of 237 bp, which was then digested with the restriction enzyme MboII (TaKaRa, Inc.) to produce either three bands of 182, 28 and 27 bp (1298AA) or two bands of 210 and 27 bp (1298CC).
METHYLATION STATUS ANALYSIS OF THE RASSF1A GENE PROMOTER REGION
The methylation status of the promoter region of the RASSF1A gene was determined by methylation-specific PCR as described previously. 22, 23 Briefly, tumour DNA was extracted with proteinase K and phenol/chloroform. Specimen DNA was modified with sodium bisulphite to convert all unmethylated (but not methylated) cytosine to uracil, followed by amplification with primers specific for methylated versus unmethylated DNA. 20
STATISTICAL ANALYSIS
All statistical analyses were performed using DW Cai, XF Liu, RG Bu et al. MTHFR polymorphisms in Chinese bladder cancer patients the SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Fisher's exact test and the χ 2 test were used to test the significance of differences in the frequencies of genotypes and the effect on hypermethylation of the RASSF1A gene promoter. The odds ratio (OR) and 95% confidence intervals (CI) were calculated to assess the relative risk conferred by a particular allele or genotype. The Hardy-Weinberg equilibrium goodness of fit was used with the χ 2 test to compare the observed versus expected genotype frequencies. A Pvalue < 0.05 was considered to be statistically significant.
Results
A total of 312 bladder cancer cases and 325 cancer-free controls were included in the study. Cases and controls were well matched in terms of age (± 5 years), sex and ethnicity. Mean ± SD age was 63.12 ± 11.25 years for bladder cancer cases and 63.73 ± 12.17 years for controls. There were no significant differences in the frequency distributions of age and sex between the bladder cancer cases and controls.
Genotype and allele frequency distributions for MTHFR C677T and A1298C among the bladder cancer cases and controls, and their associations with bladder cancer are shown in Table 1 . The observed frequencies of the three MTHFR C677T and A1298C genotypes were in Hardy-Weinberg equilibrium among controls. For the MTHFR C677T polymorphism, the difference in the frequencies of genotypes (P = 0.017) and alleles (P = 0.006) between the cases and controls was statistically significant. The MTHFR 677CT genotype was associated with (Table 1 ). There was no significant difference in MTHFR A1298C polymorphisms between cases and controls for either genotypes or alleles, nor any association between the MTHFR A1298C polymorphisms and the risk of bladder cancer.
It has been shown that the C677T and A1298C loci of the MTHFR gene are in strong linkage disequilibrium. 4 A strong linkage disequilibrium between MTHFR C677T and A1298C was also detected among the bladder cancer cases and controls (D' = 0.95); their combined genotypes are presented in Table  2 .
The combined genotype 677TT/1298AA was significantly associated with an increased risk of bladder cancer (OR 2.27, 95% CI 1.33 -3.90) compared with the genotype 677CC/1298AA.
In order to study the methylation status of the promoter region of the RASSF1A gene, surgically excised, frozen bladder cancer tissues from 45 cases were randomly selected from the 312 bladder cancer cases included in the study. A case by case approach was used to compare MTHFR C677T and MTHFR A1298C genotypes with the methylation status of the promoter region of the RASSF1A gene. Among the 45 cases, 28 were methylated and 17 unmethylated (Table 3 ). There were no significant differences in the genotype distributions for the MTHFR C677T and A1298C polymorphisms between patients with an unmethylated compared with a hypermethylated RASSF1A gene promoter.
Discussion
The In recent years, interest in genetic susceptibility to cancers has led to increased study of the gene polymorphisms that are involved in tumourigenesis. The enzyme, MTHFR, plays a central role in the metabolic pathway involved in both DNA methylation and DNA synthesis. 14 The association between MTHFR gene polymorphisms and the risk of bladder cancer has been examined in many studies, but the results have been inconsistent. For example, Moore et al. 24 reported that the MTHFR 677CT and TT genotypes had a protective effect against bladder cancer, particularly among patients who had never smoked. In contrast, Heijmans et al. 11 found that individuals from the USA who were carrying the MTHFR 677TT genotype were at significantly increased risk of bladder cancer and kidney cancer, and Wang et al. 4 found that the MTHFR 677TT genotype was significantly associated with an increased risk of bladder cancer. In contrast, Kimura et al. 13 found that MTHFR C677T genotypes did not contribute to susceptibility to bladder cancer. In the present study in a Chinese population, it was found that individuals carrying the MTHFR 677TT genotype were associated with an increased risk of bladder cancer. A smaller increased risk of bladder cancer was The discrepancy of results from all these studies may be due to differences in ethnic background, differences in environmental exposure, dietary intake of folate, smoking status, alcohol use and arsenic exposure. Several studies have revealed that the MTHFR 677T allele is protective when the dietary folate level is adequate but a risk when the folate level is deficient. 11, 14, 20 As the epidemiological data reported in the present study lacked any information on dietary intake of folate, it was not possible to address the role of folate intake.
Polymorphisms in the MTHFR gene are believed to affect methyl group metabolism which, in turn, may influence epigenetic changes in cancer. To the authors' knowledge, to date few studies have been conducted to investigate the association between the MTHFR gene polymorphisms and RASSF1A promoter hypermethylation in cancers, and the results of these studies are inconsistent. Kang et al. 18 reported that the heterozygous MTHFR 677CT genotype was significantly associated with decreased promoter hypermethylation of the O 6methylguanine DNA methyltransferase (MGMT) gene, and the MTHFR variants were not related to hypermethylation of the RASSF1A gene promoter in uterine cervical cancer. Siraj et al. 25 found no significant association between the MTHFR variants and methylation of the MGMT and fragile histidine triad (FHIT) genes in diffuse large B-cell lymphoma.
The present study is the first to investigate the association between MTHFR polymorphisms and hypermethylation of the RASSF1A gene promoter in bladder cancer in Chinese patients. A high frequency (62.22%) of hypermethylation of the promoter region of the RASSF1A gene was found in bladder cancer patients, which is in agreement with another study, 26 but no association was observed between hypermethylation of the promoter region of the RASSF1A gene and MTHFR polymorphisms in bladder cancer. The present study was underpowered, however, and the results should be confirmed by largescale epidemiological studies fully to exclude the possibility of an association between promoter hypermethylation and polymorphism in the MTHFR gene.
In conclusion, the present study in a Chinese population suggests that MTHFR C677T polymorphism increases the risk of bladder cancer. In combined MTHFR genotypes, 677TT/1298AA may confer the greatest risk of bladder cancer. The polymorphisms of MTHFR were found not to be associated with methylation status of the RASSF1A gene promoter region.
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